JOHN LARIVIERE: Open Payments
NPI 1982214136 · COLORADO SPRINGS, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$799 in 34 payments from 16 companies in 2025. Trend: 2023 $457 · 2024 $443 · 2025 $799
Food & beverage: $799
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 4 | $90 |
| AstraZeneca Pharmaceuticals LP | 4 | $85 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $84 |
| Ardelyx, Inc. | 3 | $82 |
| Travere Therapeutics, Inc. | 3 | $71 |
| Amgen Inc. | 2 | $59 |
| Novo Nordisk Inc | 2 | $57 |
| Alexion Pharmaceuticals, Inc. | 2 | $50 |
| Fresenius USA Marketing, Inc. | 2 | $38 |
| GlaxoSmithKline, LLC. | 2 | $38 |
Products named: Kerendia, IBSRELA, KRYSTEXXA, ULTOMIRIS, Fabhalta, Vanrafia, LOKELMA, VELPHORO.
Industry payments across CO — which companies pay providers there.
